NIH – Page 5 – Communicable Diseases Research

The mystery of COVID-19 reinfections: A global systematic review and meta-analysis

Systematic Review / Meta-analysis

Published on 2021-12-042022-10-04
Journal: Annals of Medicine and Surgery [Category] 변종,

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

SARS-CoV-2 감염의 조기 치료를 위한 Fluvoxamine: 현재 증거 검토

Review

Published on 2021-12-012022-09-11
Journal: Drugs [Category] SARS, 비임상, 임상,

[키워드] anti-inflammatory effect Anti-inflammatory effects appear available data breath Canada cause Clinical deterioration clinician condition controlled trials COVID-19 COVID-19 pandemic COVID-19 treatment COVID-19 treatment guidelines current cytokine production Decision making Dosing early treatment Efficacy fluvoxamine Infection inhibitor investigators knowledge long-lasting mechanism medication meeting morbidity morbidity and mortality NIH observational study potential mechanism potential mechanisms Psychiatric randomized clinical trial Randomized controlled trial receptor reduce Research review Safe SARS-CoV-2 SARS-COV-2 infection selective Sepsis Serotonin Treatment Trial USA
[DOI] 10.1007/s40265-021-01636-5 PMC 바로가기 [Article Type] Review

Religious identity cues increase vaccination intentions and trust in medical experts among American Christians

432

Published on 2021-11-182022-10-29
Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19,

Randomized Controlled Study to Test the Effectiveness of Developmental Network Coaching in the Career Advancement of Diverse Early-Stage Investigators (ESIs): Implementation Challenges and Lessons Learned

Randomized Controlled Trial

Published on 2021-11-162022-10-04
Journal: International Journal of Environmental Research an [Category] MERS, SARS, 임상,

[키워드] added Adding advancement affected African Americans Algorithms Analysis Asian assistant Associate Blinding career career development challenge Characteristics Coaching Cohort Controlled COVID-19 COVID-19 pandemic demographics developmental developmental networks distribution Diversity early-stage investigators ENhance ESI foundation grant writing group implementation Intervention Latinx lesson mechanism mentorship mock study section National Research Mentoring Network (NRMN) nested cluster randomization network NIH outcomes pandemic participant predictor Professor randomization recruit recruited Research Resolution Sample size Science Section Sex significantly Study design Support Test
[DOI] 10.3390/ijerph182212003 PMC 바로가기 [Article Type] Randomized Controlled Trial

LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)

Poster Abstracts

Published on 2021-11-042022-10-29
Journal: Open Forum Infectious Diseases [Category] COVID-19,

[키워드] 95% CI agreement Analysis AstraZeneca Asymptomatic asymptomatic infection AZD1222 Breakthrough infection Brett CDC criteria ChAdOx1 ChAdOx1 nCoV-19 clearance conducted COVID-19 COVID-19 symptom COVID-19 vaccine criteria Critical cumulative defined demonstrated doses DSMB Duration Efficacy Elizabeth employee Exploratory analysis Fee figure foundation funding highlighting implication Inc incidence Infection Jackson janssen material Merlin NIH Novavax nucleocapsid Other pandemic participant per 1000 person-year Pfizer phase Placebo placebo-controlled study positive RT-PCR Randomized reducing Result Saliva SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose Seroconversion shedding statistical Stephanie Support symptomatic symptomatic infection symptomatic infections table the primary endpoint viral clearance viral shedding Viral transmission was determined
[DOI] 10.1093/ofid/ofab466.1637 PMC 바로가기 [Article Type] Poster Abstracts

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

스페인 HIV 연구 네트워크 코호트에서 SARS-CoV-2 혈청 양성과 관련된 유병률 및 요인

Review

Published on 2021-11-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] 치료제,

[키워드] 95%CI acquisition acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted adjusted odds ratio age AIDS Analysis antiretroviral drug Antiretroviral therapy Asymptomatic backbone Birth Cancer carried CD4+ cell count chronic heart disease Chronic kidney disease cirrhosis Cohort collected Comorbidities Comorbidity coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 criteria cross-sectional cross-sectional study diabetes Diabetes Mellitus emtricitabine Factor fumarate heart disease HIV hypertension identify illness Illness severity increased the risk Infection inhibitor Kidney disease Latin Logistic regression analysis males median median age medical record medical records Multivariable logistic regression analysis network NIH nucleoside nucleotide other variables participant people with HIV plasma predictor Prevalence Prevent reverse transcriptase route sample collection SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 infections serology Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus severity Sex Spain Spanish TDF/FTC tenofovir Tenofovir alafenamide tenofovir disoproxil tenofovir disoproxil fumarate therapy transcriptase undetectable variable Viral load was used
[DOI] 10.1016/j.cmi.2021.06.023 PMC 바로가기 [Article Type] Review

Measures of physical performance in COVID-19 patients: a mapping review

COVID-19 환자의 신체 기능 측정: 매핑 검토

Review

Published on 2021-11-012022-09-11
Journal: Pulmonology [Category] 임상,

[키워드] 6MWT Abstract abstracts activity article articles assessment tool assessments Barthel Index battery CINAHL Cohort comparison Comparisons conducted Consensus Controlled trial COVID-19 COVID-19 infection COVID-19 patients cross-sectional Cross-sectional studies database Desaturation discrepancies distance Dyspnoea English language evaluated Evidence evidence of exercise Exercise capacity Exercise induced desaturation Exercise tests fatigue functional Functional status impairment inclusion criteria Infection investigator measure Measures median NIH observational studies observational study Other Pain patients patients with COVID-19 performance physical protocol Randomized controlled trial ranged rehabilitation reported resolved Sample sample sizes scored screened searched secondary Symptom Symptoms target Test variety verification walking
[DOI] 10.1016/j.pulmoe.2021.06.005 PMC 바로가기 [Article Type] Review

Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop

NeuroImmune Pharmacology COVID-19 가상 워크샵에 대한 학회

Article

Published on 2021-09-012022-09-11
Journal: Journal of neuroimmune pharmacology : the official [Category] 치료제,

The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19

Article

Published on 2021-08-262022-10-28
Journal: Biomedicines [Category] COVID-19,

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients

SARS-CoV-2 스파이크 단백질 유도 단클론 항체는 APECED 환자의 COVID-19 합병증을 개선할 수 있습니다

Clinical Trial

Published on 2021-08-242022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 임상, 진단, 치료법,

[키워드] administration Admission AIRE antibody APECED APS-1 autoantibody Autoimmune autoimmune regulator bamlanivimab bamlanivimab-etesevimab candidiasis caused center clinical Clinical effect Complication Course COVID-19 COVID-19 infection COVID-19 pneumonia COVID-19 symptom COVID-19 symptoms death develop drug early treatment Efficacy Emergency use authorization enrolled entry of SARS-CoV-2 etesevimab evaluated food high risk high-risk patient High-risk patients Hospitalization host cells IFNs immune Infection intensive care interferons interferons (IFNs invasive life-threatening loss-of-function mutation loss-of-function mutations mAb mAbs Mild-to-moderate monoclonal antibodies monoclonal antibody Neutralizing NIH nucleocapsid protein Patient patients Pneumonia Pneumonitis prophylactically protocol reduced SARS-CoV-2 SARS-CoV-2 spike protein severe disease spike Spike protein syndrome the SARS-CoV-2 type-1 IFN autoantibodies US Food and Drug Administration ventilatory support without affecting
[DOI] 10.3389/fimmu.2021.720205 PMC 바로가기 [Article Type] Clinical Trial